Solifenacin

Vesicare

Urinary antispasmodic • Antimuscarinic

QT Risk

Half-life

45-68 hours

Protein Binding

98%

Metabolized By

CYP3A4

External

M3 muscarinic receptor antagonist with bladder selectivity

Drug Class

Urinary antispasmodic

Subclass

Antimuscarinic

Vesicare

Half-life

45-68 hours

Time for plasma concentration to decrease by 50%

Protein Binding

98%

Fraction bound to plasma proteins

Therapeutic Index

Wide

Margin between therapeutic and toxic doses